The North America cell line development market size surpassed USD 1.4 billion in 2020 and is expected to witness 11% CAGR from 2021 to 2027. Hybridoma cell line segment will observe over 10% growth rate during the forecast period.

North America Cell Line Development Market Size Forecasts 2027

North America Cell Line Development Market Forecast 2027 By Source (Mammalian, Non-mammalian {Insects, Amphibians}), By Product (Reagents & Media, Equipment {Incubator, Centrifuge, Bioreactor, Storage Equipment, Microscope}, Accessories & Consumables), By Cell Line (Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line), By Application (Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology

1.1&nbsp;&nbsp;&nbsp; Methodology

1.2&nbsp;&nbsp;&nbsp; Market definitions

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; Data sources

1.4.1&nbsp;&nbsp;&nbsp; Secondary

1.4.1.1&nbsp;&nbsp;&nbsp; Paid sources

1.4.1.2&nbsp;&nbsp;&nbsp; Unpaid sources

1.4.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; North America cell line development market industry 3600 synopsis, 2016 - 2027

Chapter 3&nbsp;&nbsp;&nbsp;North America Cell Line Development Market Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry segmentation

3.2&nbsp;&nbsp;&nbsp; Industry landscape, 2016 - 2027

3.3&nbsp;&nbsp;&nbsp; Industry impact forces

3.3.1&nbsp;&nbsp;&nbsp; Growth drivers

3.3.1.1&nbsp;&nbsp;&nbsp; Growing vaccine production

3.3.1.2&nbsp;&nbsp;&nbsp; Increasing cancer prevalence

3.3.1.3&nbsp;&nbsp;&nbsp; Growth in biotechnology industry

3.3.1.4&nbsp;&nbsp;&nbsp; Innovations in biologics due to patent expirations

3.3.1.5&nbsp;&nbsp;&nbsp; Rising demand for monoclonal antibodies

3.3.1.6&nbsp;&nbsp;&nbsp; Technological innovation in cell line development

3.3.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.3.2.1&nbsp;&nbsp;&nbsp; Issues related to stem cell research

3.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Competitive review, 2020

3.5.1&nbsp;&nbsp;&nbsp; Strategy dashboard

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PEST analysis

Chapter 4&nbsp;&nbsp;&nbsp;North America Cell Line Development Market, By Product

4.1&nbsp;&nbsp;&nbsp; Key segment trends

4.2&nbsp;&nbsp;&nbsp; Reagents and media

4.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3&nbsp;&nbsp;&nbsp; Equipment

4.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3.2&nbsp;&nbsp;&nbsp; Incubators

4.3.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3.3&nbsp;&nbsp;&nbsp; Centrifuges

4.3.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3.4&nbsp;&nbsp;&nbsp; Bioreactors

4.3.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3.5&nbsp;&nbsp;&nbsp; Storage equipment

4.3.5.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3.6&nbsp;&nbsp;&nbsp; Microscopes

4.3.6.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.4&nbsp;&nbsp;&nbsp; Accessories &amp; consumables

4.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 5&nbsp;&nbsp;&nbsp;North America Cell Line Development Market, By Source

5.1&nbsp;&nbsp;&nbsp; Key segment trends

5.2&nbsp;&nbsp;&nbsp; Mammalian

5.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.3&nbsp;&nbsp;&nbsp; Non-mammalian

5.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.3.2&nbsp;&nbsp;&nbsp; Insects

5.3.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.3.3&nbsp;&nbsp;&nbsp; Amphibians

5.3.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 6&nbsp;&nbsp;&nbsp;North America Cell Line Development Market, By Cell Line Type

6.1&nbsp;&nbsp;&nbsp; Key segment trends

6.2&nbsp;&nbsp;&nbsp; Recombinant cell lines

6.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

6.3&nbsp;&nbsp;&nbsp; Hybridomas

6.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

6.4&nbsp;&nbsp;&nbsp; Continuous cell lines

6.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

6.5&nbsp;&nbsp;&nbsp; Primary cell lines

6.5.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 7&nbsp;&nbsp;&nbsp;North America Cell Line Development Market, By Application

7.1&nbsp;&nbsp;&nbsp; Key segment trends

7.2&nbsp;&nbsp;&nbsp; Bioproduction

7.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.3&nbsp;&nbsp;&nbsp; Drug discovery

7.3.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.4&nbsp;&nbsp;&nbsp; Toxicity testing

7.4.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.5&nbsp;&nbsp;&nbsp; Tissue engineering

7.5.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.6&nbsp;&nbsp;&nbsp; Research

7.6.1&nbsp;&nbsp;&nbsp; Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 8&nbsp;&nbsp;&nbsp;North America Cell Line Development Market, By Country

8.1&nbsp;&nbsp;&nbsp; Key country trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; Market estimates and forecast by country, 2016 - 2027 (USD Million)

8.2.2&nbsp;&nbsp;&nbsp; Market estimates and forecast by product, 2016 - 2027 (USD Million)

8.2.3&nbsp;&nbsp;&nbsp; Market estimates and forecast by source, 2016 - 2027 (USD Million)

8.2.4&nbsp;&nbsp;&nbsp; Market estimates and forecast by cell line type, 2016 - 2027 (USD Million)

8.2.5&nbsp;&nbsp;&nbsp; Market estimates and forecast by application, 2016 - 2027 (USD Million)

8.2.6&nbsp;&nbsp;&nbsp; U.S.

8.2.6.1&nbsp;&nbsp;&nbsp; Market estimates and forecast by product, 2016 - 2027 (USD Million)

8.2.6.2&nbsp;&nbsp;&nbsp; Market estimates and forecast by source, 2016 - 2027 (USD Million)

8.2.6.3&nbsp;&nbsp;&nbsp; Market estimates and forecast by cell line type, 2016 - 2027 (USD Million)

8.2.6.4&nbsp;&nbsp;&nbsp; Market estimates and forecast by application, 2016 - 2027 (USD Million)

8.2.7&nbsp;&nbsp;&nbsp; Canada

8.2.7.1&nbsp;&nbsp;&nbsp; Market estimates and forecast by product, 2016 - 2027 (USD Million)

8.2.7.2&nbsp;&nbsp;&nbsp; Market estimates and forecast by source, 2016 - 2027 (USD Million)

8.2.7.3&nbsp;&nbsp;&nbsp; Market estimates and forecast by cell line type, 2016 - 2027 (USD Million)

8.2.7.4&nbsp;&nbsp;&nbsp; Market estimates and forecast by application, 2016 - 2027 (USD Million)

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; GE Healthcare

9.1.1&nbsp;&nbsp;&nbsp; Business overview

9.1.2&nbsp;&nbsp;&nbsp; Financial data

9.1.3&nbsp;&nbsp;&nbsp; Product landscape

9.1.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.2&nbsp;&nbsp;&nbsp; Thermo Fisher Scientific Inc.

9.2.1&nbsp;&nbsp;&nbsp; Business overview

9.2.2&nbsp;&nbsp;&nbsp; Financial data

9.2.3&nbsp;&nbsp;&nbsp; Product landscape

9.2.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.3&nbsp;&nbsp;&nbsp; Lonza Group AG

9.3.1&nbsp;&nbsp;&nbsp; Business overview

9.3.2&nbsp;&nbsp;&nbsp; Financial data

9.3.3&nbsp;&nbsp;&nbsp; Product landscape

9.3.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.4&nbsp;&nbsp;&nbsp; Sigma-Aldrich Corporation (Merck)

9.4.1&nbsp;&nbsp;&nbsp; Business overview

9.4.2&nbsp;&nbsp;&nbsp; Financial data

9.4.3&nbsp;&nbsp;&nbsp; Product landscape

9.4.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.5&nbsp;&nbsp;&nbsp; WuXi AppTec

9.5.1&nbsp;&nbsp;&nbsp; Business overview

9.5.2&nbsp;&nbsp;&nbsp; Financial data

9.5.3&nbsp;&nbsp;&nbsp; Product landscape

9.5.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.6&nbsp;&nbsp;&nbsp; Sartorius Stedim Biotech GmbH

9.6.1&nbsp;&nbsp;&nbsp; Business overview

9.6.2&nbsp;&nbsp;&nbsp; Financial data

9.6.3&nbsp;&nbsp;&nbsp; Product landscape

9.6.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.7&nbsp;&nbsp;&nbsp; Corning Inc.

9.7.1&nbsp;&nbsp;&nbsp; Business overview

9.7.2&nbsp;&nbsp;&nbsp; Financial data

9.7.3&nbsp;&nbsp;&nbsp; Product landscape

9.7.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.8&nbsp;&nbsp;&nbsp; Selexis SA

9.8.1&nbsp;&nbsp;&nbsp; Business overview

9.8.2&nbsp;&nbsp;&nbsp; Financial data

9.8.3&nbsp;&nbsp;&nbsp; Product landscape

9.8.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.9&nbsp;&nbsp;&nbsp; GVK BIO

9.9.1&nbsp;&nbsp;&nbsp; Business overview

9.9.2&nbsp;&nbsp;&nbsp; Financial data

9.9.3&nbsp;&nbsp;&nbsp; Product landscape

9.9.4&nbsp;&nbsp;&nbsp; Strategic outlook

9.10&nbsp;&nbsp;&nbsp; Vista Biologicals

9.10.1&nbsp;&nbsp;&nbsp; Business overview

9.10.2&nbsp;&nbsp;&nbsp; Financial data

9.10.3&nbsp;&nbsp;&nbsp; Product landscape

9.10.4&nbsp;&nbsp;&nbsp; Strategic outlook 
&nbsp;